Pharvaris PHVS soars 26.68% on NDA hopes

Pharvaris(PHVS) shares surged 26.68% today, marking the third consecutive day of gains, with a cumulative increase of 39.71% over the past three days. The share price reached its highest level since March 2024, with an intraday gain of 29.90%.

The strategy of buying PHVS shares after reaching a recent high and holding for one week resulted in a 106.82% return, vastly outperforming the benchmark, which returned -100.00%. The strategy achieved an excess return of 206.82% and a CAGR of 33.73% over the past five years. Although the strategy had a maximum drawdown of 79.19%, it maintained a positive Sharpe ratio of 0.43, indicating good risk-adjusted returns.

Pharvaris's stock price has been influenced by recent updates regarding their pivotal Phase 3 RAPIDe-3 study. In July 2025, the company announced that the release of topline data would be postponed until the fourth quarter of 2025. Despite this delay, investors remain optimistic about the potential for positive data, which could lead to the submission of a New Drug Application (NDA) in the first half of 2026. This anticipation has contributed to the recent surge in Pharvaris's stock price.

Investors are closely monitoring the progress of Pharvaris's RAPIDe-3 study, as the outcome will significantly impact the company's future prospects. The delay in data release has not dampened investor enthusiasm, as the potential for a successful NDA submission continues to drive positive sentiment. The company's strategic decisions and the market's response to these updates highlight the dynamic nature of the biotech sector and the importance of clinical trial outcomes in shaping investor expectations.